IMPAKT Breast Cancer Conference
Brussels, Belgium, 4-6 May 2017

Call for abstracts

Abstract submission deadline:
1 February 2017
23:59hrs Central European Time (CET)

Submission methods and deadlines

All abstracts for the 8th IMPAKT Breast Cancer Conference (IMPAKT 2017) must be submitted by Wednesday, 1 February 2017.

Abstract submission is free of charge and must be completed online only via the IMPAKT 2017 website, http://www.esmo.org/Conferences/IMPAKT-2017-Breast-Cancer

Abstracts submitted by e-mail, post or fax will not be accepted.

Submission categories

Detection and diagnosis
Early breast cancer systemic therapy
Loco-regional therapy
Advanced breast cancer systemic therapy
Genomics and proteomic analysis of breast cancer
Biomarkers in breast cancer (prognostic, predictive and pharmacodynamic)
Breast cancer host immune and stromal biology
Mechanisms of metastasis
Imaging (preclinical and clinical)
Preclinical breast cancer biology
Breast cancer target identification and validation and preclinical models
New drug development
Miscellaneous
Submission regulations

1. By submitting an abstract intended for presentation at IMPAKT 2017, the first author (= presenter) warrants that any material which has been previously published in any publication in peer-review setting or presented at a meeting of any other scientific organisation prior to IMPAKT 2017 has been reworded and/or updated.

2. Abstracts submitted after the deadline or containing infractions of the following rules will be rejected and returned without consideration by the IMPAKT 2017 Scientific Committee.

3. The first author may, but does not need to be, an ESMO member.

4. With the submission of an abstract, and on behalf of him/herself and all co-authors, the first author (= presenter) undertakes to:

i. Release full copyright to the Breast International Group (BIG) and the European Society for Medical Oncology (ESMO), jointly “the IMPAKT 2017 organisers” and give full permission for the abstract, if accepted, to be published in the IMPAKT 2017 Abstract Book in electronic format, as well as published online on the BIG, ESMO and Oxford University Press websites. Accepted abstracts will be published as a supplement of the official ESMO journal Annals of Oncology.

ii. Warrant that he/she is an investigator with a substantial involvement in the study presented in the abstract.

iii. Confirm that all authors are aware of, and agree to, the content of the abstract and support the data therein; furthermore the first author will be responsible for obtaining, and, upon request, showing proof that all authors have given their permission for the submission of the abstract and content therein as well as for the potential inclusion of the abstract in the official IMPAKT 2017 Press Programme.

iv. Accept responsibility for the accuracy and confidentiality (see corresponding section) of the submitted abstract.

v. Indicate where applicable the number of trial protocol (NIH or European equivalent) and release date (when it was obtained).

vi. Acknowledge any editorial assistance in the writing of the abstract that was provided by a third party, providing the name of the writer and the company who provided this service.

vii. Declare the name of the legal entity responsible for the governance, coordination and running of the study.

viii. Declare how the study detailed in the abstract was funded, for example by a pharmaceutical, biotech or other commercial company or by a Foundation or academic group, and to name the organisation(s) funding the study.

ix. Ensure that all authors identify any financial interest in products or processes involved in their research. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships.

x. Ensure that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and that properly informed consent, where appropriate, has been given.

xi. Certify that the study reported in the abstract will not be presented as such during the Conference at any industry-related Satellite symposia prior to its presentation during the official IMPAKT 2017 programme.

xii. Present his/her abstract if it is selected for presentation at IMPAKT 2017 as an Oral presentation or Poster.

xiii. Indicate whether he/she agrees to participate in the official IMPAKT 2017 Press Programme if the abstract is selected for press coverage by the IMPAKT 2017 organisers, and guarantee that he/she is not subject to any restrictions by the institute he/she belongs to.

xiv. Indicate whether the abstract is submitted in association with an application for a travel grant.

xv. Be the presenter and contact person for all correspondence concerning the abstract and to keep co-authors duly informed about its status. The first author may nominate a co-author to present an accepted abstract at the IMPAKT 2017 and or during the official Press Programme provided that the name of the replacement is submitted by E-mail to the organisers c/o the ESMO Congress Department (programme@esmo.org / ESMO Press Office media@esmo.org) within 24 hours of outcome notification.
5. Withdrawal of abstracts

If the first author wishes to withdraw his/her abstract from IMPAKT 2017 after outcome notifications (Oral or Poster presentation) have been made available, he/she must submit a written request within 24 hours to the organisers c/o programme@esmo.org. Any abstract withdrawal requests made after 24 hours cannot be assured of removal from the IMPAKT 2017 Abstract Book.

6. No-show policy

The abstract’s first author (= presenter) who, without notice, is absent during the session when his/her abstract is presented will be barred from having abstracts accepted for the following IMPAKT Breast Cancer Conference.
Submission instructions

- Each section of the online abstract submission system must be completed. Authors failing to give all information required in the online submission system will not have their abstract considered by the IMPAKT 2017 Scientific Committee.

- Once each step is completed, the author must go to the Preview and Finish section and click 'Finish Submission' in order to complete the process. Without clicking this option, the abstract will not be considered as submitted and will not be forwarded to the IMPAKT 2017 Scientific Committee for consideration.

- Abstracts should adequately describe research objectives and results. Each abstract should contain an introductory sentence indicating the purpose of the study, a brief description of pertinent methodological procedures, a summary of the new, unpublished results data and a statement of conclusions.

- The title of the abstract should include significant words that reflect the content of the abstract but not refer to the study results or conclusions.

- Commercial names may not be used in the title of the abstract. Compounds should be mentioned with the generic name in lower case. Commercial names are admitted in the text, with the ® symbol, and if in brackets following the generic name, i.e. ‘generic (Commercial®)’. The IMPAKT 2017 Scientific Committee reserves the right to substitute commercial names with generic names where necessary without further recourse to the authors.

- Names of cooperative study groups should appear in the title, as they will not be reported in the author index.

- Abbreviations may be used in the title and text of abstracts if they are defined. Terms must be spelt out in full at its first mention and followed with the abbreviation in parentheses. Particular care should be taken to identify complex chemotherapeutic regimens.

- The character limit for all submitted abstracts is set at 2,000, excluding spaces. This limit includes characters entered in the title, abstract body and table fields (default of 225 characters per table) but not the author names and institutions.

- Illustrations are not permitted. Brief and clear tables are accepted.

- The maximum number of authors allowed per abstract is limited to 10 (ten). Mailing addresses, academic degrees and professional positions such as Medical Director, CEO, CMO etc. must NOT be mentioned.

- Authors must select the submission category of their abstract, however, the IMPAKT 2017 Scientific Committee reserves the right to re-categorise abstracts without further recourse to the authors.

- Authors must select their preferred choice of presentation: Oral or Poster presentation; however, the decision of the IMPAKT 2017 Scientific Committee will be final.

- Each abstract must be accompanied by a minimum of one and maximum of four keywords. The IMPAKT 2017 Scientific Committee reserves the right to assign different keywords without further recourse to the authors.

- The use of good English and proof-reading is essential. Once the abstract is submitted, online changes, corrections or rewording will not be possible. The IMPAKT 2017 Scientific Committee reserves the right to reject abstracts which are presented in poor English or to request an immediate revision by the first author.

- Supplementary data such as manuscripts will not be accepted or forwarded to the IMPAKT 2017 Scientific Committee.

- The first author (= presenter) must indicate if the abstract is submitted in association with an application for a travel grant.

- Abstracts on case reports will be rejected.
Presentation and publication of accepted abstracts

The IMPAKT 2017 Scientific Committee will select abstracts for presentation during the Conference and determine the format of the presentations from the following possibilities:

- **Best Abstracts Sessions** (Oral presentation) – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.

- **Poster** – An important method for communicating details of scientific research, posters will be on display for the duration of the Conference. A Poster Walk, where participants will have the opportunity to discuss selected posters with both their authors and experts in the field, will be scheduled in the programme.

All accepted abstracts will be published online in the IMPAKT 2017 Abstract Book.

Detailed instructions for the preparation of visual presentations and posters will be made available on the IMPAKT website in February 2017 along with scheduling notices.

Publication schedule of accepted abstracts

1. Abstracts accepted for poster presentation during IMPAKT 2017 will be published online on the Conference website on **Thursday, 27 April 2017**.

2. Abstracts selected for oral presentation and/or for the official IMPAKT Press Programme will be made public at the beginning of the Conference.

<table>
<thead>
<tr>
<th>Abstracts accepted as:</th>
<th>27 April 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Posters (suffix ‘P’)</td>
<td></td>
</tr>
</tbody>
</table>

**EXCEPT:**

<table>
<thead>
<tr>
<th>Abstracts accepted as:</th>
<th>Beginning of IMPAKT 2017 10:30 on 4 May 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstracts selected for Best Abstract Session (suffix ‘O’)</td>
<td></td>
</tr>
<tr>
<td>Abstracts selected for official IMPAKT Press Programme (additional suffix '_PR')</td>
<td></td>
</tr>
</tbody>
</table>
Confidentiality policy

Abstracts submitted to IMPAKT 2017 are considered confidential until publicly released in connection with the IMPAKT 2017 meeting. Prior to public release, the author, co-authors, research sponsors, journalists and others may not:

- Make the information public or provide it to others who can make it public (e.g. press);
- Publish or present the information or provide it to others who can make it public;
- Use the information for trading purposes or provide it to others who can use it for trading purposes.

If information from the abstract or additional study data are disclosed in advance of public release in connection with IMPAKT 2017, the abstract will no longer be eligible for inclusion in the IMPAKT 2017 programme and/or will be subject to removal.

Confidentiality policy exceptions

According to the Confidentiality policy, data and other information in a research abstract is confidential from the time the abstract is submitted to IMPAKT 2017 until public release in connection with IMPAKT 2017.

When a publicly traded company is required to disclose data or other information from a confidential abstract in advance of the public release to satisfy requirements of the US Securities and Exchange Commission (SEC) or a corresponding body in another country, the abstract is still eligible for inclusion in the IMPAKT 2017 programme provided that the company submits to the IMPAKT 2017 Secretariat c/o the ESMO Press Office (media@esmo.org) in advance of the release written notification of the requirement to issue information in accordance to SEC regulations.

In the interest of effective peer-reviewed presentation of data at IMPAKT 2017, and particularly if the abstract has been tentatively included in the official IMPAKT 2017 Press Programme, the company is required to get in contact with the IMPAKT Secretariat c/o the ESMO Press Office in advance of the release to notify that a press release regarding an abstract included in the official IMPAKT 2017 Press Programme will have to be issued in accordance to SEC regulations.

The IMPAKT 2017 organisers recommend that the company’s press release adheres to the Qualitative Sample Press Release (provided by the IMPAKT Secretariat c/o the ESMO Press Office) and:

1. Summarises data cited in the abstract in a qualitative way rather than providing specific quantitative information, including exact figures on the study.
2. Avoids interpretations about the implications of the data for clinical practice.
3. Notes that full data has been submitted to, and will be presented at, IMPAKT 2017 in an official programme session.

The IMPAKT Secretariat c/o the ESMO Press Office will review the company’s press release to ensure it adheres to the Qualitative Sample Press Release and evaluate if the abstract can still be included in the official IMPAKT 2017 Press Programme.

If the press release includes significantly more information than the IMPAKT’s recommendations, the abstract’s placement in IMPAKT 2017 is subject to change and can be withdrawn from the official IMPAKT 2017 Press Programme.
Travel grants

A restricted number of travel grants to IMPAKT 2017 are available, upon application, to first author (= presenter) of candidates under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by the IMPAKT 2017 Scientific Committee on a competitive basis from among the accepted abstracts.

To apply for a travel grant, the following documents must be received by the IMPAKT Secretariat c/o the ESMO Congress Department on or before 1 February 2017:

1. A letter of introduction by the applicant. Please include the following general information:
   • How relevant are the topics presented during this Conference to your current practice and research?
   • Have you attended any event on a similar topic in the last 3 years?
   • How do you believe your attendance at this Conference will help you improve your knowledge in the field and your professional development?
   • How do you consider that the findings published in your abstract make a relevant contribution to the topics presented during this Conference?
   • Have you recently been awarded an ESMO travel grant? If yes, for which event?

2. A copy of the submitted abstract (the applicant must be the first author and presenter)

3. A readable photocopy of either identity card or passport


Documentation must be sent by E-mail to impakt@esmo.org

The IMPAKT 2017 organisers will provide the recipients with a subsidised travel ticket, subsidised accommodation and Conference registration.

Travel grant recipients must submit a report detailing the benefits of participating in IMPAKT 2017 by 13 June 2017.

Incomplete applications will not be considered.